|Tuesday, 7 February 2017, 16:30 HKT/SGT|
|Oncology industry veteran to oversee operations and product commercialization|
Paris, France and Cambridge, Massachusetts, USA, Feb 7, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
Mr. Dostie will lead Nanobiotix's operations, including development, manufacturing, market access and sales, for the Company's lead product NBTXR3, which could obtain a CE Mark approval in 2017. Previously, Mr. Dostie was the Oncology General Manager at Novartis Germany. He joins Nanobiotix with over 25 years of international experience in the pharmaceutical industry, particularly in market access and oncology.
Laurent Levy, CEO of Nanobiotix, commented: "We are thrilled to welcome Alain to the Nanobiotix team as our company takes major strides to enter a new phase in its development. His experience and values make Alain the perfect person to join the team to play this crucial role."
Mr. Dostie added, "Nanobiotix is at the tipping point of its value creation with the coming first Phase II/III interim readout and a potential first market approval this year. The unique, unrivaled and broadly applicable technology developed by Nanobiotix, along with the strong and enthusiastic team, attracted me to the Company. I am very excited to join the Company at such an important time and contribute to its long-term success."
Prior to joining Nanobiotix, Mr. Dostie served as the Oncology General Manager at Novartis Pharma GmbH in Germany, where he managed a team of several hundred of people and was responsible for more than $1 billion in sales. Previously, he served within the Novartis group as Oncology General Manager Canada and Oncology Business Unit Head in the Czech Republic and Slovakia. He also served as Executive Marketing Director and National Sales Director positions in oncology at Novartis Pharmaceuticals Canada, Inc., Government Affairs Manager at Merck Frosst Canada, Inc. and various positions within Bayer Canada Inc. and Millipore Canada during his early career. Mr. Dostie earned his Bachelor of Science in human kinetics from the University of Guelph, in Ontario, Canada.
About NANOBIOTIX www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Director, Communication & Public Affairs
+33 (0)1 40 26 07 55
firstname.lastname@example.org / email@example.com
Director, Investor Relations
+1 (646) 241-4400
firstname.lastname@example.org / email@example.com
France - Springbok Consultants
+33 (0)6 71 58 00 34
United States - RooneyPartners
+1 (212) 223-4017
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the update of the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732-A01 on December 27, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via Globenewswire
Feb 7, 2017 16:30 HKT/SGT
Topic: Press release summary
Sectors: Science & Research, BioTech, HealthCare
From the Asia Corporate News Network
Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Nov 13, 2017 15:00 HKT/SGT|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting|
|Nov 10, 2017 08:30 HKT/SGT|
Nanobiotix provides update on the global development of its lead product NBTXR3|
|Oct 23, 2017 14:00 HKT/SGT|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|Sept 29, 2017 08:00 HKT/SGT|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.|
|Sept 1, 2017 01:30 HKT/SGT|
Nanobiotix half year results for the six months ended 30 June 2017|
|June 16, 2017 06:00 HKT/SGT|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop|
|June 6, 2017 00:00 HKT/SGT|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting|
|May 18, 2017 14:00 HKT/SGT|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology|
|Apr 29, 2017 01:00 HKT/SGT|
Nanobiotix: 2016 Annual Results|
|Apr 4, 2017 14:50 HKT/SGT|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology|
|More news >>|